Clinical study on the effect of desomumab on osteoporotic fracture healing

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2200062124

Enrollment

Unknown

Registered

2022-07-23

Start date

2022-08-01

Completion date

Unknown

Last updated

2023-04-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Osteoporosis fracture

Interventions

Desomumab injection group:Desomumab was injected subcutaneously

Basic treatment group:oral calcium tablets + vitamin D

Eligibility

Sex/Gender

All

Age

61 Years to 90 Years

Inclusion criteria

Inclusion criteria: 1.It met the diagnostic criteria of OVCF and was confirmed by clinical examination and imaging examination; 2.There was no nerve compression, no spinal cord compression on imaging, all were fresh compression fractures of vertebral body 3.All patients gave informed consent; 4.Follow-up visits were completed 6 months /1 year after treatment.

Exclusion criteria

Exclusion criteria: 1. Allergic; 2. Without informed consent; 3. Patients with malignant tumor, severe liver and kidney dysfunction, etc., which may affect the outcome indicators.

Design outcomes

Primary

Measure	Time frame
Bone mineral density;X-ray;	—

Countries

CHINA

Contacts

Public ContactJiang Xiaobing

The First Affiliated Hospital of Guangzhou University of Chinese Medicine

spinedrjxb@sina.com13632494486

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026